** Shares of Telix Pharmaceuticals rise as much as 7.4% to A$25.79, their biggest gain since Sept. 20, 2024
** Stock hits highest level since Dec. 18, 2024 ** The biopharmaceutical co records revenue of $517 mln in FY, beating its forecast of $490 mln to $510 mln
** Co reports 55% y-o-y growth in full-year revenue ** Stock is among the top 10 performers on ASX 200 benchmark
** Shares gained 144.1% in 2024
(Reporting by Jasmeen Ara Shaikh in Bengaluru) ((mailto:Jasmeenaraislam.shaikh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.